tiprankstipranks
Trending News
More News >
BioLargo Inc (BLGO)
OTHER OTC:BLGO
US Market

BioLargo (BLGO) AI Stock Analysis

Compare
65 Followers

Top Page

BL

BioLargo

(OTC:BLGO)

Rating:49Neutral
Price Target:
$0.00
▼(-100.00%Downside)
BioLargo's revenue growth is a positive indicator, but consistent losses and negative cash flow are significant concerns impacting financial stability. The technical indicators suggest bearish momentum, while valuation metrics show challenges due to negative earnings.

BioLargo (BLGO) vs. SPDR S&P 500 ETF (SPY)

BioLargo Business Overview & Revenue Model

Company DescriptionBioLargo, Inc. invents, develops, and commercializes various platform technologies. The company's technologies solve challenging environmental problems comprising per- and polyfluoroalkyl substances contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. It holds various issued patents, maintains a pipeline of products, and provides full-service environmental engineering services. The company's products include Advanced Oxidation system, a water treatment device that generates a series of oxidative and energetic species of iodine and other molecules; Aqueous Electrostatic Concentrator, a water treatment system that removes per- and poly-fluoroalkyl substances from water; CupriDyne Clean industrial products, which reduce and eliminate tough odors and volatile organic compounds in various industrial settings; and advanced wound care products. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.
How the Company Makes MoneyBioLargo makes money through the sale and licensing of its proprietary technologies and products. Key revenue streams include direct sales of their water treatment systems and odor control products to industrial and municipal clients, as well as licensing agreements for the use of their patented technologies. The company also generates income through strategic partnerships with other organizations that leverage BioLargo's innovations to enhance their own product offerings. Additionally, consulting services provided by BioLargo Engineering, Science & Technologies (BLEST) contribute to the company's revenue by offering specialized expertise in environmental engineering projects.

BioLargo Earnings Call Summary

Earnings Call Date:May 15, 2025
(Q4-2024)
|
% Change Since: -16.67%|
Next Earnings Date:Aug 19, 2025
Earnings Call Sentiment Positive
BioLargo's earnings call presented a positive outlook, with significant revenue growth and advancements across its subsidiaries. However, challenges in specific projects and revenue fluctuations in key products indicate areas needing attention. Overall, the sentiment is optimistic with caution regarding operational hurdles.
Q4-2024 Updates
Positive Updates
Significant Revenue Growth
BioLargo achieved an overall sales and revenue increase of 45%, reaching nearly $18 million. The growth was driven by various subsidiaries, showcasing an accelerated growth path.
Impressive Subsidiary Performance
Odor-No-More saw a revenue increase of 36%, generating $5.9 million in operating income. The engineering division also experienced revenue growth of 183%.
Positive Balance Sheet Developments
BioLargo reported a strong balance sheet, maintaining $3.5 million in cash, increased accounts receivable due to business development, and reduced overall debt.
Pooph Product Success
The Pooph product line, with eight unique products and 15 SKUs, has been performing exceptionally well in retail, contributing significantly to revenue growth.
Clyra Medical Nearing Market Readiness
Clyra Medical is approaching the launch of its innovative product, with significant investments in manufacturing and a successful inspection confirming scale capability.
Negative Updates
Pooph Revenue Fluctuations
Despite its success, Pooph product revenue experienced an ebb and flow, with a noted decrease in Q4 compared to Q3, potentially due to marketing spend adjustments.
Delayed AEC Projects
Projects related to the AEC technology, such as the New Jersey installation, have faced delays due to external factors like weather and construction timelines.
Garratt-Callahan Partnership Challenges
The partnership with Garratt-Callahan for minimum liquid discharge units has not yielded the expected results, with adoption challenges cited.
Battery Technology Validation Delays
Third-party validation for the Spartan cell battery technology has been slower than anticipated, with efforts ongoing to secure necessary validation.
Company Guidance
In the BioLargo Annual 2024 Earnings Results call, the company provided several key metrics that underscore its growth and future potential. The company reported a 45% increase in overall sales and revenue, reaching nearly $18 million. Specific subsidiaries also showed significant growth, with Odor-No-More's revenue increasing by 36%, contributing $5.9 million in operating income. The engineering division saw a 183% increase in third-party revenue, although it still operated at a loss of $1.45 million, down from $1.6 million the previous year. Clyra Medical Technologies, a subsidiary focused on medical products, was identified as the majority contributor to the net loss, which decreased to $4.3 million from $4.6 million. Moreover, the company highlighted substantial investments and partnerships, particularly in the battery and PFAS sectors, indicating a multibillion-dollar opportunity in battery technology and significant cost-saving potential in PFAS treatment. BioLargo also maintained a strong balance sheet with $3.5 million in cash and an increase in accounts receivable, reflecting its expanding business. The company aims to continue its upward trajectory with strategic partnerships and product innovations, setting the stage for potential exits and increased shareholder value.

BioLargo Financial Statement Overview

Summary
BioLargo exhibits strong revenue growth from $1.86M in 2019 to $17.78M in 2024, but faces challenges with profitability and cash flow. Net losses persist with a $2.40M loss in 2024 and operational cash flow remains negative, indicating financial management challenges.
Income Statement
45
Neutral
BioLargo has demonstrated significant revenue growth, increasing from $1.86M in 2019 to $17.78M in 2024, showing a strong upward trajectory. However, the company remains unprofitable with consistent net losses, including a net loss of $2.40M in 2024. The gross profit margin has improved but remains volatile. EBIT and EBITDA margins remain negative, indicating operational challenges.
Balance Sheet
50
Neutral
BioLargo's financial stability is supported by a strong equity position with a debt-to-equity ratio significantly improved over the years, now at 0.17. The equity ratio is healthy at 84.18%. However, the company has high leverage in earlier years and a history of negative net debt, indicating potential liquidity risks.
Cash Flow
40
Negative
Operating cash flow has been consistently negative, reflecting ongoing operational cash burn. Free cash flow growth has not been positive, and the free cash flow to net income ratio remains challenging. While financing activities have supported cash needs, sustained negative cash flows pose a risk to long-term financial health.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue16.29M17.78M12.23M5.88M2.53M2.43M
Gross Profit7.10M7.85M6.15M2.86M1.10M1.23M
EBITDA-5.13M-4.06M-4.19M-5.10M-6.70M-7.83M
Net Income-3.15M-2.40M-3.50M-4.50M-7.38M-10.47M
Balance Sheet
Total Assets10.51M10.51M8.21M4.86M3.02M4.94M
Cash, Cash Equivalents and Short-Term Investments2.56M3.55M3.54M1.85M962.00K716.00K
Total Debt1.43M2.55M1.70M1.47M1.13M2.67M
Total Liabilities2.05M4.46M4.00M2.85M2.09M5.18M
Stockholders Equity7.61M8.85M6.84M4.88M4.65M3.86M
Cash Flow
Free Cash Flow-5.89M-4.44M-2.84M-3.03M-3.97M-4.18M
Operating Cash Flow-5.52M-3.21M-2.37M-2.76M-3.94M-4.15M
Investing Cash Flow-454.00K-1.32M-478.00K-271.00K-34.00K-123.00K
Financing Cash Flow4.22M4.44M4.66M3.96M4.23M4.34M

BioLargo Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.20
Price Trends
50DMA
0.21
Negative
100DMA
0.24
Negative
200DMA
0.23
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
43.74
Neutral
STOCH
39.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLGO, the sentiment is Negative. The current price of 0.2 is below the 20-day moving average (MA) of 0.20, below the 50-day MA of 0.21, and below the 200-day MA of 0.23, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 43.74 is Neutral, neither overbought nor oversold. The STOCH value of 39.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BLGO.

BioLargo Risk Analysis

BioLargo disclosed 44 risk factors in its most recent earnings report. BioLargo reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

BioLargo Peers Comparison

Overall Rating
UnderperformOutperform
Sector (43)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
VHVHI
73
Outperform
$516.66M4.4411.76%1.77%7.82%19465.71%
LXLXU
55
Neutral
$583.65M-5.28%-4.23%-259.01%
54
Neutral
$276.45M-10.12%2.20%34.71%
FFFF
54
Neutral
$176.97M11.43-3.29%5.75%-33.92%-58.53%
53
Neutral
$84.36M-26.63%-11.91%-26768.00%
49
Neutral
$60.88M-40.03%22.97%17.32%
43
Neutral
AU$1.41B-6.02-40.74%3.99%-3.45%-41.76%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
BLGO
BioLargo
0.20
-0.06
-23.08%
FF
Futurefuel
4.10
-0.57
-12.21%
LXU
Lsb Industries
8.23
0.74
9.88%
VHI
Valhi
18.76
3.21
20.64%
RYAM
Rayonier Advanced Materials
4.14
-1.29
-23.76%
ORGN
Origin Materials
0.60
-0.25
-29.41%

BioLargo Corporate Events

Shareholder MeetingsStock SplitBusiness Operations and Strategy
BioLargo Approves Proposals at Annual Meeting
Neutral
Jun 25, 2025

At its 2025 annual stockholder meeting on June 19, 2025, BioLargo, Inc. announced the approval of all proposals, including the election of board members and the authorization for a potential reverse stock split. Although the reverse stock split was approved, the board has no immediate plans to implement it, intending to do so only if necessary for uplisting to a national exchange. CEO Dennis Calvert highlighted the company’s strategic positioning and readiness to expand its market reach and attract institutional investors when conditions are favorable.

Other
BioLargo Presents at Webcast Investor Conference
Neutral
May 15, 2025

BioLargo, Inc. presented a slide presentation at a webcast investor conference on May 15, 2025. The information shared during this event is not considered filed with the SEC and the company does not have an obligation to update it, although it may choose to do so in the future.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 21, 2025